Eurozone Debt Crisis: Effects on PIIGS Pharmaceuticals Market
Published: 24 May 2010
- 18 pages
- PDF delivery via email, hard copies via first-class mail
Catalogue Price: $580.00
Web Price: $490.00
You save: $90.00 (15%) on the regular rate
Product Description
Business Monitor International (BMI)'s special report `Eurozone Debt Crisis: Effects On PIIGS Pharma Market' analyses the implications of the Eurozone sovereign debt crisis on the PIIGS pharmaceutical industries, with a particular focus on the impact of austerity measures on drug sales.
The report looks at current governmental controls in place on the pharmaceutical industry and the economic outlook for each PIIGS country.
Key Findings
- Amongst the PIIGS countries (Portugal, Italy, Ireland, Greece and Spain) price cuts will not be confined to Greece, with each country likely to implement cuts to reduce government pharma spending in 2010.
- Price erosion mechanisms across Europe will continue to be accelerated by governments looking to cut costs in this area.
- Drug prices within Europe will be affected by Greek austerity measures targeting the industry, short-term price cuts coupled with longer-term price erosion.
- Industry associations fear the possible industry impacts of such cuts including multinational exits, damage to local companies and closure of manufacturing plants.
- Companies exposed to European markets will see revenues and valuations majorly impacted even if aggregate price decreases are only a few percent.